 Health Care |
Health Care |
|
|
Pfizer falls in line with Trump's 'Most Favored Nation' plan |
Pfizer CEO Albert Bourla announced in the Oval Office that his company will offer all its prescription medications to Medicaid at discounted prices in line with the rates paid by other countries. |
The move acceded to the demands in President Trump's "Most Favored Nation" executive order, which aims to bring down U.S. drug prices and linking them to lower prices overseas. "The United States is done subsidizing the health care of the rest of the world," Trump said Tuesday. Pfizer's vast product portfolio includes cancer therapies like Ibrance and Xtandi as well as its COVID-19 products like its vaccine and the antiviral Paxlovid. Trump sent a letter to drug companies in July demanding they provide preferential pricing to all Medicaid patients, required that they not give better prices to other developed countries on new drugs, create a way to sell directly to consumers and use trade policy to raise prices internationally so that revenue is reinvested into lowering American prices. Those who refused risked facing "every tool in our arsenal to protect American families from continued abusive drug pricing practices," according to Trump's letter. "With this deal that we signed today, we satisfied all four of [the] president's requests, all four," Bourla said. Senior administration officials said talks are ongoing with other drugmakers, though Trump said Eli Lilly was among companies that would soon be announcing deals with the administration. The Pfizer CEO has previously chafed against price-control measures, once calling Medicare negotiations established through the Inflation Reduction Act "not negotiation at all. It is price setting." Trump said he used the threat of tariffs to bring drug companies to the negotiating table. Bourla said Trump "graciously" gave his company a three-year grace period from tariffs. |
Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel and Joseph Choi — every week we follow the latest moves on how Washington impacts your health. |
|
| How policy will be impacting the health care sector this week and beyond: |
|
|
President Trump signed an executive order on Tuesday aimed at using artificial intelligence to improve research and treatments for childhood cancer. The order builds on a 2019 database established by Trump that collects data on childhood cancer. That order directs agencies to use artificial intelligence to analyze information in that database to accelerate research and clinical trials. "Using cutting-edge AI, we will empower … |
| |
|
The Trump administration on Tuesday announced plans to launch TrumpRx.com, an online platform that it says will direct Americans to lower-priced drugs. The announcement came one day after President Trump’s deadline for drugmakers to comply with his “Most Favored Nation” (MFN) executive order, which included a mandate for companies to establish direct-to-consumer for medicines, cutting out middlemen. Chris … |
| |
|
Branch out with a different read: |
|
|
Newsom labels Vance 'dips—' over migrant health care spending claim |
California Gov. Gavin Newsom (D) on Monday labeled Vice President Vance a "dips—" due to a claim the vice president made about health care spending for migrants. In a clip posted by the White House's rapid response on the social platform X account Monday, Vance said Democrats had put forward "a $1.5 trillion spending package, basically saying to the American people, 'We want to give massive amounts of money, hundreds … |
|
|
Local and state headlines on health care: |
|
|
Health news we've flagged from other outlets: |
- Layoffs to hit beleaguered CDC if there's a shutdown (Roll Call)
- FDA head says he got the agency 'exempted' from possible shutdown RIFs (NOTUS)
- Home hospital programs in 'terror' as they grind to halt ahead of government shutdown (Stat)
|
|
|
Opinions related to health submitted to The Hill: |
|
|
You're all caught up. See you tomorrow! |
400 N Capitol Street NW Suite 650, Washington, DC 20001 |
Copyright © 1998 - 2025 Nexstar Media Inc. | All Rights Reserved. |
|
|
|
If you believe this has been sent to you in error, please safely unsubscribe.
No comments:
Post a Comment